WST WEST PHARMACEUTICAL SERVICE...

NYSE westpharma.com


$ 264.95 $ 0.00 (0 %)    

Thursday, 16-Oct-2025 04:14:56 EDT
QQQ $ 604.98 $ 0.00 (0 %)
DIA $ 463.26 $ 0.00 (0 %)
SPY $ 667.22 $ 0.00 (0 %)
TLT $ 91.10 $ 0.00 (0 %)
GLD $ 390.40 $ 0.00 (0 %)
$ 262.95
$ 261.34
$ 263.75 x 5
$ 267.34 x 1
-- - --
$ 187.09 - $ 351.24
605,179
na
18.91B
$ 1.05
$ 38.77
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-24-2025 06-30-2025 10-Q
2 04-24-2025 03-31-2025 10-Q
3 02-18-2025 12-31-2024 10-K
4 10-24-2024 09-30-2024 10-Q
5 07-25-2024 06-30-2024 10-Q
6 04-25-2024 03-31-2024 10-Q
7 02-20-2024 12-31-2023 10-K
8 10-26-2023 09-30-2023 10-Q
9 07-27-2023 06-30-2023 10-Q
10 04-27-2023 03-31-2023 10-Q
11 02-21-2023 12-31-2022 10-K
12 10-27-2022 09-30-2022 10-Q
13 07-28-2022 06-30-2022 10-Q
14 04-28-2022 03-31-2022 10-Q
15 02-22-2022 12-31-2021 10-K
16 10-28-2021 09-30-2021 10-Q
17 07-30-2021 06-30-2021 10-Q
18 04-30-2021 03-31-2021 10-Q
19 02-23-2021 12-31-2020 10-K
20 10-23-2020 09-30-2020 10-Q
21 07-24-2020 06-30-2020 10-Q
22 04-24-2020 03-31-2020 10-Q
23 02-24-2020 12-31-2019 10-K
24 10-29-2019 09-30-2019 10-Q
25 07-29-2019 06-30-2019 10-Q
26 05-08-2019 03-31-2019 10-Q
27 02-28-2019 12-31-2018 10-K
28 10-30-2018 09-30-2018 10-Q
29 07-31-2018 06-30-2018 10-Q
30 05-08-2018 03-31-2018 10-Q
31 02-26-2018 12-31-2017 10-K
32 10-31-2017 09-30-2017 10-Q
33 08-01-2017 06-30-2017 10-Q
34 05-05-2017 03-31-2017 10-Q
35 02-28-2017 12-31-2016 10-K
36 10-31-2016 09-30-2016 10-Q
37 08-01-2016 06-30-2016 10-Q
38 05-06-2016 03-31-2016 10-Q
39 02-26-2016 12-31-2015 10-K
40 11-02-2015 09-30-2015 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 barclays-maintains-equal-weight-on-west-pharmaceutical-servs-raises-price-target-to-275

Barclays analyst Luke Sergott maintains West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight and raises the price target...

 looking-into-west-pharmaceutical-servss-recent-short-interest

West Pharmaceutical Servs's (NYSE: WST) short interest as a percent of float has risen 9.25% since its last report. Accordi...

 rothschild--co-initiates-coverage-on-west-pharmaceutical-servs-with-buy-rating-announces-price-target-of-311

Rothschild & Co analyst Jamie Clark initiates coverage on West Pharmaceutical Servs (NYSE:WST) with a Buy rating and ann...

 thermo-fisher-baker-hughes-and-iqvia-holdings-are-among-top-10-large-cap-gainers-last-week-july-21-july-25-are-the-others-in-your-portfolio

Medpace, ICON, and West Pharma led last week's large-cap rally, driven by strong earnings beats and upgraded guidance.

 ubs-maintains-buy-on-west-pharmaceutical-servs-raises-price-target-to-320

UBS analyst John Sourbeer maintains West Pharmaceutical Servs (NYSE:WST) with a Buy and raises the price target from $285 to...

 evercore-isi-group-maintains-outperform-on-west-pharmaceutical-servs-raises-price-target-to-350

Evercore ISI Group analyst Daniel Markowitz maintains West Pharmaceutical Servs (NYSE:WST) with a Outperform and raises the ...

 west-pharma-lifts-outlook-on-surging-glp-1-demand-stock-soars

West Pharmaceutical raised its 2025 EPS and sales guidance after Q2 earnings and revenue topped estimates, fueled by strong dem...

 west-pharmaceutical-servs-raises-fy2025-adj-eps-guidance-from-615-635-to-665-685-vs-629-est-raises-fy2025-sales-guidance-from-2945b-2975b-to-3040b-3060b-vs-2961b-est

Full-Year 2025 Financial GuidanceThe Company is increasing its full-year 2025 net sales guidance range to $3.040 billion to $3....

 west-pharmaceutical-names-robert-mcmahon-as-new-cfo-succeeding-retiring-finance-chief-bernard-birkett

West Pharmaceutical Services, Inc. (NYSE:WST), a global leader in innovative solutions for injectable drug administration, toda...

 barclays-initiates-coverage-on-west-pharmaceutical-servs-with-equal-weight-rating-announces-price-target-of-245

Barclays analyst Luke Sergott initiates coverage on West Pharmaceutical Servs (NYSE:WST) with a Equal-Weight rating and anno...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION